Search

Your search keyword '"van der Ende, M. E."' showing total 146 results

Search Constraints

Start Over You searched for: Author "van der Ende, M. E." Remove constraint Author: "van der Ende, M. E."
146 results on '"van der Ende, M. E."'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Management of drug interactions with direct‐acting antivirals in Dutch HIV/hepatitis C virus‐coinfected patients: adequate but not perfect

3. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

7. High-Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1-Infected Persons Does Not Result in Sustained Suppression of Viral Replication

16. Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort

17. Transmission networks of HIV-1 among men having sex with men in the Netherlands

18. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

19. Primary resistance to integrase strand-transfer inhibitors in Europe

20. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

21. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in the Netherlands before and after Transition to Adult Care

22. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

23. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

24. Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in the Netherlands before and after Transition to Adult Care

25. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort

26. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

27. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

28. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

29. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

30. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

32. Has the Rate of CD4 Cell Count Decline before Initiation of Antiretroviral Therapy Changed over the Course of the Dutch HIV Epidemic among MSM?

33. Limited cross-border infections in patients newly diagnosed with HIV in Europe

34. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

35. Dendritic cell-based immune therapy against HIV-1

36. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

37. Seksuele overdracht van hepatitis C bij homoseksuele mannen

39. Behandeling van HIV-I in Nederland: Virologische en immunologische respons op antiretrovirale therapie

40. De haalbaarheid en de zin. Post-expositie-profylaxe

41. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

42. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group

43. Substituting nevirapine for protease inhibitors because of intolerance

44. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group

46. Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV

Catalog

Books, media, physical & digital resources